Downregulation of circulating exosomal miR-638 predicts poor prognosis in colon cancer patients

Shushan Yan; Guangwang Dang; Xiaoyu Zhang; Chengwen Jin; Lang Qin; Yugang Wang; Min Shi; Haijin Huang; Quanhong Duan

doi:10.18632/oncotarget.19689

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Downregulation of circulating exosomal miR-638 predicts poor prognosis in colon cancer patients

Shushan Yan, Guangwang Dang, Xiaoyu Zhang, Chengwen Jin, Lang Qin, Yugang Wang, Min Shi, Haijin Huang and Quanhong Duan _

PDF | HTML | How to cite

Oncotarget. 2017; 8:72220-72226. https://doi.org/10.18632/oncotarget.19689

Metrics: PDF 2009 views | HTML 2276 views | ?

Abstract

Shushan Yan1,*, Guangwang Dang2,*, Xiaoyu Zhang3,*, Chengwen Jin4, Lang Qin5, Yugang Wang6, Min Shi6, Haijin Huang7 and Quanhong Duan1

1Department of Gastrointestinal and Anal Diseases Surgery, The Affiliated Hospital of Weifang Medical University, Weifang, China

2Department of Outpatient, People’s Hospital of Zoucheng, Zoucheng, China

3Division of Gastrointestinal Surgery, Department of General Surgery, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, China

4Functional Laboratory, Clinical Medicine College of Weifang Medical University, Weifang, China

5Department of Image, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

6Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

7Department of General Surgery, Hongze District People's Hospital, Hongze, China

*These authors have contributed equally to this work

Correspondence to:

Quanhong Duan, email: [email protected]

Haijin Huang, email: [email protected]

Keywords: colon cancer, exosomes, microRNA-638, prognosis

Received: May 13, 2017 Accepted: June 19, 2017 Published: July 29, 2017

ABSTRACT

Exosome-encapsulated microRNAs have been recognized as novel and stable biomarkers for cancer. However, little is known about the role of exosomal microRNAs in colon cancer. In the present study, we investigated the expression of serous exosomal microRNA-638 (miR-638) and its prognostic effect in patients with colon cancer. Serous exosomal samples were assayed by quantitative real-time PCR. Kaplan-Meier analysis was adopted to determine the overall survival (OS) and disease-free survival (DFS) of colon cancer patients. Cox regression analysis was applied to assess the potential association between serous exosomal miR-638 and clinicopathological factors of colon cancer patients. MiR-638 was significantly reduced in serum exosomes of colon cancer patients compared with healthy controls. Decreased level of serous exosomal miR-638 was more significant in colon cancer patients at later TNM stage or with liver metastasis. Kaplan-Meier analysis showed that colon cancer patients with reduced level of serous exosomal miR-638 had poor OS and DFS. In addition, the Cox regression analysis suggested serous exosomal miR-638 was a prognostic factor for colon cancer independent of TNM stage and liver metastasis. In conclusion, serous exosomal miR-638 is a useful biomarker for the prediction of colon cancer prognosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19689

Publication Alerts

Research Papers:

Downregulation of circulating exosomal miR-638 predicts poor prognosis in colon cancer patients

Abstract